ProQR Prices $50.0 Million Underwritten Registered Direct Offering and Concurrent Private Placement
Rhea-AI Summary
ProQR (Nasdaq: PRQR) priced an underwritten registered direct offering of 27,624,310 ordinary shares at $1.81 per share, targeting $50 million in gross proceeds. A concurrent private placement to Eli Lilly adds about $9.2 million, both expected to close around June 26, 2026.
According to ProQR, net proceeds plus existing cash will mainly fund research and clinical development, alongside working capital and general corporate purposes.
Positive
- Underwritten registered direct offering targets approximately $50.0 million in gross proceeds
- Concurrent private placement with Eli Lilly adds about $9.2 million
- Eli Lilly purchase allows it to maintain pro rata beneficial ownership in ProQR
- Net proceeds earmarked to fund research and clinical development of RNA pipeline
- Multiple bookrunners (BofA Securities, Evercore ISI, Cantor, Oppenheimer) support capital raise
Negative
- Issuance of over 32.7 million new ordinary shares will dilute existing shareholders
- Concurrent private placement shares are unregistered and subject to resale restrictions under the Securities Act
News Market Reaction – PRQR
In the Jun 25 session, PRQR declined 13.54%, reflecting a significant negative market reaction. Argus tracked a peak move of +22.0% during that session. Argus tracked a trough of -34.9% from its starting point during tracking. Our momentum scanner triggered 20 alerts that day, indicating elevated trading interest and price volatility. Trading volume was very high at 4.7x the daily average, suggesting heavy selling pressure.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Private placement,offering Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Oct 25 | Equity offering | Negative | -4.3% | Closing of underwritten public offering and Lilly private placement raising $75.3M. |
| Oct 22 | Equity offering | Negative | -7.7% | Pricing of $75M public offering plus Lilly private placement to maintain ownership. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Prior equity offerings and private placements have reliably led to negative next-day price reactions for PRQR.
Key Terms
underwritten registered direct offering financial
concurrent private placement financial
shelf registration statement regulatory
form f-3 regulatory
prospectus supplement regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEIDEN, Netherlands and CAMBRIDGE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (“ProQR”), a clinical-stage biotechnology company dedicated to changing lives through transformative RNA therapies based on its proprietary Axiomer™ RNA editing technology platform, today announced the pricing of an underwritten registered direct offering of 27,624,310 ordinary shares (the “Offering”) at an offering price of
Concurrently with the Offering, ProQR has entered into a share purchase agreement with Eli Lilly and Company (“Lilly”), one of its existing shareholders and a strategic partner, in a separately negotiated transaction pursuant to which ProQR agreed to offer and sell, and Lilly agreed to purchase, 5,100,780 ordinary shares, to permit Lilly to maintain its pro rata beneficial ownership, at the Offering Price, for total gross proceeds of approximately
The ordinary shares to be sold in the concurrent private placement are being issued pursuant to the exemptions provided by Section 4(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). These shares have not been registered under the Securities Act, or any state or other applicable jurisdiction’s securities laws, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the Securities Act and applicable state or other jurisdiction’s securities laws.
ProQR currently intends to use the net proceeds from the Offering and the concurrent private placement, together with its existing cash and cash equivalents, primarily to fund research and clinical development of its current or additional pipeline candidates and for working capital, capital expenditures and other general corporate purposes.
BofA Securities, Evercore ISI and Cantor are acting as joint lead bookrunning managers for the Offering, and Oppenheimer & Co. is acting as a bookrunning manager for the Offering. The Offering and concurrent private placement are expected to close on or about June 26, 2026, subject to the satisfaction of customary closing conditions.
A shelf registration statement on Form F-3 relating to the Offering (including the accompanying prospectus) was filed with the Securities and Exchange Commission (the “SEC”) on September 30, 2024 and was declared effective on October 10, 2024. The Offering is being made only by means of a prospectus and prospectus supplement that form a part of the registration statement. A final prospectus supplement relating to and describing the final terms of the Offering will be filed with the SEC. When available, copies of the final prospectus supplement and the accompanying prospectus relating to the Offering may be obtained from: BofA Securities, NC1-022-02-25, Attention: Prospectus Department, 201 North Tryon Street, Charlotte, NC, 28255-0001, or by email at dg.prospectus_requests@bofa.com; Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at (888) 474-0200 or by email at ecm.prospectus@evercore.com; or Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022 or by email at prospectus@cantor.com. You may also obtain these documents free of charge by visiting the SEC’s website at www.sec.gov.
This press release shall not constitute an offer to sell, or a solicitation of an offer to buy these securities, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies. ProQR is pioneering a next-generation RNA technology called Axiomer™, which uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unmet need. Based on its unique proprietary RNA repair platform technologies ProQR is growing its pipeline with patients and loved ones in mind.
Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,” “intend,” “look forward to,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would” and similar expressions. Forward-looking statements are based on management’s beliefs and assumptions and on information available to management only as of the date of this press release. These forward-looking statements include, but are not limited to, statements about the expected timing, completion and intended use of proceeds of the Offering and the concurrent private placement. Such forward-looking statements involve risks and uncertainties, many of which are beyond ProQR’s control, including risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the Offering and the concurrent private placement. There can be no assurance that ProQR will be able to complete the Offering and the concurrent private placement on the anticipated terms, or at all. Applicable risks also include those that are included in ProQR’s final prospectus supplement and accompanying prospectus to be filed with the SEC for the Offering, including the documents incorporated by reference therein, which include ProQR’s Annual Report on Form 20-F for the year ended December 31, 2025, and any subsequent SEC filings. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and ProQR assumes no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor and media contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Investor contact:
Peter Kelleher
LifeSci Advisors
T: +1 617 430 7579
pkelleher@lifesciadvisors.com
